Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
JonesTrading Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
Maintaining Buy Rating on Coherus Biosciences Amid Temporarily Disrupted Supply Chain
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)
UBS Cuts Coherus to Neutral, Cites Limited Growth Opportunities
Coherus BioSciences Analyst Ratings
UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5
Strong Performance and Promising Outlook Justify Outperform Rating for Coherus Biosciences
Buy Rating Justified by Coherus Biosciences' Strong Udenyca Sales and Promising Pipeline
Coherus BioSciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed for Coherus Biosciences on Strong Oncology Focus and Financial Resilience